Drug intelligence / Profile preview

GT-1

Development stage: Unknown
Modality: Small Molecules

Overview

GT-1 (LCB10-0200) is a novel synthetic antibacterial compound designed to combat Gram-negative bacterial infections. It exhibits potent activity against a range of Gram-negative pathogens, addressing a critical need in antibiotic development where few new agents target this bacterial class effectively. Developed as part of efforts to expand the antibacterial pipeline, GT-1 represents a small molecule with potential utility in treating infections caused by multidrug-resistant Gram-negative bacteria, though specific developers and clinical progression details are limited in available data.

Targets

TBDT (TonB-dependent receptor)

Beyond the preview

Go deeper on GT-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT-1.

Explore the full profile